Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/gatheraround/wp-includes/functions.php on line 6114
Dr Emily Harrold - Gathering Around Cancer Skip to content

Dr Emily Harrold

Dr Emily Harrold is currently a medical oncology consultant at the Trinity St James Cancer Institute at St James’s Hospital in Dublin where she holds both a clinical and genetic appointment. She is part of the Young Onset Cancer Programme team. She previously completed an advanced oncology fellowship in Memorial Sloan Kettering Cancer Centre in New York where her research focused on genetic predisposition syndromes and the impact of novel therapeutics on mitigating cancer risk. She is a University College Dublin Medical School graduate who completed her specialist Medical Oncology training in Ireland through the Royal College of Physicians of Ireland.

Her career to date has been distinguished by both Irish and international awards including ISMO Bursary awards, the Paddy Johnston Colorectal Cancer Research Award and most recently ASCO Special Merit Awards at the annual ASCO meetings in 2022 and in 2023 for her research evaluating the risk of neoplasia in patients with Lynch syndrome post immunotherapy treatment and somatic-germline integration to evaluate the contribution of non-classical germline pathogenic variants to colorectal carcinogenesis.

She was also awarded a Conquer Cancer ASCO Young investigator Grant in April 2023 to further expand her study, in collaboration with the BROAD institute, in patients with Lynch syndrome treated with immunotherapy.

Her research interests include cancer immunology, mechanisms of resistance to immunotherapy, inherited cancer genetics and early onset cancers both in cohorts defined by pathogenic germline variants and those without.